Shore Capital Group Reiterates “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital Group in a report released on Wednesday, Marketbeat Ratings reports.

GSK has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft increased their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 price target on shares of GSK in a research note on Wednesday, January 7th. UBS Group reiterated a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, Citigroup raised their price objective on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research note on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of GBX 1,966.43.

GSK Price Performance

Shares of GSK stock opened at GBX 2,046 on Wednesday. The stock has a market cap of £82.07 billion, a price-to-earnings ratio of 14.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.32. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a 50 day moving average price of GBX 2,035.68 and a 200-day moving average price of GBX 1,827.29. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 2,282.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities analysts expect that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In other news, insider Luke Miels sold 15,579 shares of the business’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Also, insider Anne Beal purchased 196 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was bought at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Insiders have acquired a total of 11,447 shares of company stock valued at $24,273,097 in the last three months. 0.26% of the stock is owned by company insiders.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK continued its share repurchase programme, buying 345,000 ordinary shares and lifting treasury holdings to 6.27% of voting rights — reduces float and supports EPS and per‑share metrics. Buyback Update
• Positive Sentiment: GSK Pakistan reported a 53% jump in profit to Rs. 10 billion for 2025 — strong regional operating performance that can add to group profitability and investor confidence in emerging‑market franchise momentum. GSK Pakistan Profit GSK Pakistan Profit (alt)
• Positive Sentiment: GSK struck an alliance with Shanghai Pharma to reintroduce its hepatitis B vaccine in China — expands access to a large market and supports vaccine growth prospects. China Hep B Alliance
• Positive Sentiment: Insider buying reported (Jonathan Symonds 5,000 shares; Wendy Becker 411 shares) — small but constructive insider signal that can reassure investors. Insider Buys – Symonds Insider Buys – Becker
• Positive Sentiment: Shore Capital reaffirmed a “buy” rating — an additional buy‑side endorsement that may attract demand. Shore Capital Buy
• Neutral Sentiment: GSK presented at the Goldman Sachs Biopharma Innovation Summit (transcript available) — useful for investor visibility on pipeline and strategy but unlikely to move the stock unless new data or guidance were announced. Goldman Sachs Presentation
• Negative Sentiment: Berenberg reiterated a “hold” with a GBX 2,000 price target — below the recent trading level and signals limited near‑term upside from that broker, which can act as a headwind to further gains. Berenberg Hold/Price Target

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.